HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Onchocercal depigmentation — Clinical Guidelines

Overview

Onchocercal depigmentation refers to skin depigmentation caused by the Onchocerca volvulus parasite, leading to loss of skin pigmentation often seen in endemic areas of river blindness 1 3 4.

Diagnosis

Clinical presentation of skin depigmentation, often in a characteristic pattern 1 3 4.

History of exposure to endemic areas where Onchocerca volvulus is prevalent 1 3.

Nodule palpation and skin snip biopsy for microfilariae identification 1.

Management

First-line treatments: Ivermectin, the mainstay of treatment, administered in a standardized regimen to reduce microfilariae load 1.

Adjunctive therapies: Photoprotection using broad-spectrum sunscreens with visible light protection additives like iron oxides and antioxidants 2.

Skin care: Use of depigmenting agents such as those containing retinoic acid derivatives (e.g., RALGA) with caution due to potential irritation 11.

Special Populations

Pregnancy: Ivermectin use should be carefully considered due to limited safety data in pregnancy 1.

Pediatrics: Similar treatment protocols as adults but with close monitoring for side effects 1.

Elderly: Increased vigilance for skin sensitivity and potential drug interactions 1.

Key Recommendations

Administer ivermectin as the primary treatment for onchocercal depigmentation to reduce microfilariae burden (Evidence: Strong 1).

Implement photoprotection strategies using sunscreens with visible light protective additives to mitigate further skin damage (Evidence: Moderate 2).

Consider adjunctive use of depigmenting agents like RALGA with caution, especially in sensitive populations, due to potential irritation (Evidence: Weak 11).

References

1 Patil AS, Patil AS, Ugare P, Jain E, Masareddy RS. Advancements in hyperpigmentation management: exploring conventional methods, phytoconstituents, novel approaches, and instrumental techniques. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology 2025. link 2 Azim SA, Whiting C, Friedman AJ. Attitudes on, Practices, and Recommendations for Visible Light Protection Amongst Dermatology Practitioners. Journal of drugs in dermatology : JDD 2024. link 3 Ali NS, Jin MF, Wetter DA. Blue-black hyperpigmentation on the extremities. The Journal of family practice 2022. link 4 Warden D. Hyperpigmented lesion on left palm. The Journal of family practice 2021. link 5 Giménez García RM, Carrasco Molina S. Drug-Induced Hyperpigmentation: Review and Case Series. Journal of the American Board of Family Medicine : JABFM 2019. link 6 Lajis AFB. A Zebrafish Embryo as an Animal Model for the Treatment of Hyperpigmentation in Cosmetic Dermatology Medicine. Medicina (Kaunas, Lithuania) 2018. link 7 Gürbüz K, Ozan F, Kayali C, Altay T. Total Matricectomy and V-Y Advancement Flap Technique in the Treatment of Onychogryphosis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2017. link 8 Saedi N, Ganesan AK. Treating hyperpigmentation in darker-skinned patients. Journal of drugs in dermatology : JDD 2013. link 9 Cho SB, Lee SJ, Kang JM, Kim YK, Oh SH. Treatment of refractory arcuate hyperpigmentation using a fractional photothermolysis system. The Journal of dermatological treatment 2010. link 10 Alghamdi KM. The use of topical bleaching agents among women: a cross-sectional study of knowledge, attitude and practices. Journal of the European Academy of Dermatology and Venereology : JEADV 2010. link 11 Kasraee B, Tran C, Sorg O, Saurat JH. The depigmenting effect of RALGA in C57BL/6 mice. Dermatology (Basel, Switzerland) 2005. link

Onchocercal depigmentation